

HALE AND DORR LLP
C O U N S E L O R S A T L A W

haledorr.com

60 STATE STREET • BOSTON, MA 02109
617-526-6000 • FAX 617-526-5000

FAX

FAX RECEIVED

AUG 13 2003

GROUP 1600

Total Number of Pages: 5

Fax / Phone:

To: Philip Gambel, Ph.D.
U.S. Patent and Trademark Office

(703) 746-7293 / (703) 308-3997

From: Joseph Koipally
617-526-6026

Date: August 6, 2003

Note:

Dear Examiner Gambel:

As per our telephone message of this afternoon, please find attached amended claims for USSN: 09/350,202 and USSN: 09/349,915.

Thank you.

Sincerely,
Joseph Koipally

Unofficial

This facsimile transmission is confidential and may be privileged. If you are not the intended recipient, please immediately call the sender or, if the sender is not available, call 617-526-5413, and destroy all copies of this transmission. If the transmission is incomplete or illegible, please call the sender or, if the sender is not available, call 617-526-5413. Thank you.

Client Matter Number: 36119-125
Return To: 2924

Transmitted by:

Sharon Matthews

BOSTON LONDON MUNICH NEW YORK OXFORD PRINCETON RESTON WALTHAM WASHINGTON

Hale and Dorr LLP is a Massachusetts Limited Liability Partnership

USSN: 09/350,202

DRAFT

PROPOSED AMENDMENTS TO USSN: 09/350,202

Claim 50. (Currently Amended): A method for inducing *ex vivo* proliferation of a population of T cells, comprising:

contacting a population of T cells *ex vivo* with a solid phase surface having covalently attached thereto:

(a) a first agent which provides a primary activation signal in the T cells, thereby activating the T cells and

(b) ~~a second agent~~ an anti-CD28 antibody which stimulates an accessory molecule on the surface of the T cells, thereby stimulating the activated T cells, wherein the first agent and ~~second agent~~ the anti-CD28 antibody are covalently attached to the same solid phase surface,

the first ~~agent~~ and ~~second agents~~ the anti-CD28 antibody thereby inducing the population of T cells to proliferate.

Claim 51. (Previously Added): The method of claim 50, wherein the first agent stimulates a TCR/CD3 complex-associated signal in the T cells.

Claim 52. (Previously Added): The method of claim 50, wherein the first agent is an anti-CD3 antibody.

Claim 53. (Previously Added): The method of claim 52, wherein the anti-CD3 antibody is an anti-human CD3 monoclonal antibody.

Claim 54. (Previously Presented): The method of claim 50, wherein the accessory molecule on the T cell is CD28.

Claim 55. (Cancelled): The method of claim 54, wherein the second agent is an anti-CD28 antibody.

Claim 56. (Previously Cancelled)